Saturday, October 3, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· March 16, 2026

Top Research Reports for Philip Morris, Lam Research & Goldman Sachs

View original at finance.yahoo.com
Top Research Reports for Philip Morris, Lam Research & Goldman Sachs Monday, March 16, 2026 The Zacks Research Daily presents the best research output of our analyst team…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Foundry/logic, DRAM and NAND investments are expected to be higher year over year

    60% confidence
  • Goldman Sachs is refocusing on the core strengths of investment banking and trading businesses through restructuring and scaling back its consumer banking footprint

    60% confidence
  • Philip Morris faces premium valuations, ongoing global cigarette volume declines and rising regulatory pressure

    60% confidence
  • Smoke-free products accounted for about 43% of total gross profit in full-year 2025 for Philip Morris

    60% confidence
  • Philip Morris faces premium valuations, ongoing global cigarette volume declines and rising regulatory pressure

    60% confidence
  • For 2026, adjusted earnings per share are likely to be $8.38-$8.53, up 11.1%-13.1% year-over-year

    60% confidence
  • Lam Research is riding on its strength across 3D DRAM and advanced packaging technologies

    60% confidence
  • Goldman Sachs beat earnings estimates in each of the trailing four quarters

    60% confidence
  • Global spending on mature nodes is likely to remain soft in the near term

    60% confidence
  • Growing trade and tariff tensions between the United States and China are a concern for Lam Research

    60% confidence
  • Foundry/logic, DRAM and NAND investments are expected to be higher year over year for Lam Research

    60% confidence
  • Eastern's cyclical weakness in heavy truck and automotive markets drove an 8.7% sales decline and margin compression

    60% confidence
  • Goldman Sachs' high dependence on overseas revenues is worrisome

    60% confidence
  • Eastern faces cyclical weakness in heavy truck and automotive markets that drove an 8.7% sales decline and margin compression

    60% confidence
  • Goldman Sachs is refocusing on the core strengths of investment banking and trading businesses through restructuring and scaling back its consumer banking footprint

    60% confidence
  • Growing trade and tariff tensions between the United States and China are a concern for Lam Research

    60% confidence
  • For 2026, Philip Morris adjusted earnings per share are likely to be $8.38-$8.53, up 11.1%-13.1% year-over-year

    60% confidence
  • Palladyne is facing risks which include sustained cash burn relative to revenues, early-stage product maturity, intense competition from large robotics and defense contractors, and potential revenue variability tied to government procurement cycles

    60% confidence
  • Lam Research is riding on its strength across 3D DRAM and advanced packaging technologies

    60% confidence
  • Management's 2026 revenue outlook is roughly $24-$27 million versus about $5-$5.5 million in 2025

    60% confidence
  • Philip Morris has been benefiting from strong pricing power and an expanding smoke-free portfolio

    60% confidence
  • Management's 2026 revenue outlook of roughly $24–$27 million versus about $5–$5.5 million in 2025

    60% confidence
  • Palladyne faces risks including sustained cash burn relative to revenues, early-stage product maturity, intense competition from large robotics and defense contractors, and potential revenue variability tied to government procurement cycles

    60% confidence
  • Smoke-free products accounted for about 43% of total gross profit in full-year 2025

    60% confidence
  • Goldman Sachs beat earnings estimates in each of the trailing four quarters

    60% confidence
  • A rebound in the System business due to improving memory spending is an upside for Lam Research

    60% confidence
  • Goldman Sachs' expansion in the private equity credit market is expected to diversify revenues base and will support its growth over the long run

    60% confidence
  • Growing etch and deposition intensity owing to increasing technology inflections in 3D architectures is a plus for Lam Research

    60% confidence
  • Goldman Sachs' high dependence on overseas revenues is worrisome

    60% confidence
  • Goldman Sachs' expansion in the private equity credit market is expected to diversify revenues base and will support its growth over the long run

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com